#USA #Pleasanton #Roche Diagnostics #cobas eplex #respiratory pathogens

Roche Introduces cobas eplex Respiratory Pathogen Panel 3

Roche Diagnostics has launched a groundbreaking diagnostic tool known as the cobas® eplex respiratory pathogen panel 3 (RP3), aimed at diagnosing respiratory infections with remarkable speed and accuracy. Available in CE-mark-accepting countries, this innovative test is set to revolutionize how clinicians manage respiratory illnesses, particularly during peak seasons when these infections typically surge.

Comprehensive Detection of Respiratory Pathogens

The cobas eplex RP3 test is designed to detect a range of up to 25 viruses and bacteria, including SARS-CoV-2, influenza types A and B, Bordetella parpertussis, and RSV, from a single patient sample. What makes this tool particularly valuable is its ability to provide healthcare professionals with rapid results, empowering them to make informed and urgent treatment decisions—especially critical for high-risk patients. Josh Lauer, the Global Head of Molecular Labs at Roche, stated, “In respiratory care, time is everything. Knowing exactly what is making a patient sick allows clinicians to make fast, effective decisions that can save lives.”

Advantages for Healthcare Providers

During peak respiratory seasons, which pose significant challenges for healthcare systems, the cobas eplex RP3 panel aids clinicians in delivering targeted care promptly. The test's efficiency not only reduces time patients spend in emergency rooms but also helps hospitals manage infection control measures effectively. It requires less than one minute of hands-on time to initiate, making it user-friendly for laboratory staff and optimizing workflow.

The RP3 panel further helps clinicians avoid unnecessary antibiotic use, thereby improving patient outcomes as they can start the right treatments without delay. The cobas eplex RP3 also facilitates effective management of isolation beds, ensuring that infectious patients are kept separate from others wanting to avoid further spread of contagious diseases.

Enhanced Features of the RP3 Panel

The RP3 is a qualitative in vitro diagnostic test designed to simplify laboratory processes with features like automated result reporting and external control tracking. It runs on the cobas eplex system, which assists in streamlining laboratory work. The panel not only encompasses common pathogens but also includes newer strains that may not have previously been covered, thus providing a holistic approach to respiratory diagnostics. In addition, labs can customize testing by selecting up to five distinct panels based on local trends and patient needs, thus enhancing its utility in varied healthcare settings.

Roche's Commitment to Healthcare

Roche has a longstanding commitment to healthcare innovation, having been founded in Basel, Switzerland in 1896. Today, it stands as a leader in diagnostics and therapeutic solutions across more than 150 countries. The company focuses on addressing significant healthcare challenges with a vision to improve lives through advanced science and technology collaboration.

Through its Diagnostics and Pharmaceutical divisions, Roche primarily aims to tackle pressing health issues such as oncology, infectious diseases, and chronic conditions. The cobas eplex RP3 is just one of the many innovations Roche has unveiled to improve patient experiences and outcomes, especially for communities at high risk of respiratory infections.

For further information on Roche and its offerings, visit www.roche.com.

Final Thoughts

The launch of the cobas eplex respiratory pathogen panel 3 signifies a vital step in managing respiratory infections effectively. With tools like these, clinicians can tackle the complex landscape of respiratory care with confidence and precision, ultimately preserving lives and easing the burden on healthcare systems during critical times.

For more details, contact:

• - Yvette Petillon, Group Media Relations: +41 79 961 92 50, [Yvette's Email]
• - Brien Mahoney, Molecular Labs Communications: +1 925 699 8512, [Brien's Email]